[HTML][HTML] New approaches to SCLC therapy: from the laboratory to the clinic
JT Poirier, J George, TK Owonikoko, A Berns… - Journal of Thoracic …, 2020 - Elsevier
The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …
[HTML][HTML] PLK1 inhibition-based combination therapies for cancer management
Polo-like kinase I (PLK1), a cell cycle regulating kinase, has been shown to have oncogenic
function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) …
function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) …
Mesoporous silica nanoparticles for the treatment of complex bone diseases: Bone cancer, bone infection and osteoporosis
Bone diseases, such as bone cancer, bone infection and osteoporosis, constitute a major
issue for modern societies as a consequence of their progressive ageing. Even though …
issue for modern societies as a consequence of their progressive ageing. Even though …
Non-proteolytic ubiquitylation in cellular signaling and human disease
Ubiquitylation is one of the most common post-translational modifications (PTMs) of proteins
that frequently targets substrates for proteasomal degradation. However it can also result in …
that frequently targets substrates for proteasomal degradation. However it can also result in …
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma
PSMD4/Rpn10 is a subunit of the 19S proteasome unit that is involved with feeding target
proteins into the catalytic machinery of the 26S proteasome. Because proteasome inhibition …
proteins into the catalytic machinery of the 26S proteasome. Because proteasome inhibition …
N (6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma
S Tatekawa, K Tamari, R Chijimatsu, M Konno… - Scientific reports, 2022 - nature.com
In pancreatic cancer, methyltransferase-like 3 (METTL3), a N (6)-methyladenosine (m6A)
methyltransferase, has a favorable effect on tumors and is a risk factor for patients' …
methyltransferase, has a favorable effect on tumors and is a risk factor for patients' …
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer
ABSTRACT Introduction Polo Like Kinase 1 (PLK1) is a key regulator of mitosis and its
overexpression is frequently observed in a wide variety of human cancers, while often being …
overexpression is frequently observed in a wide variety of human cancers, while often being …
How microtubules build the spindle branch by branch
SM Travis, BP Mahon, S Petry - Annual review of cell and …, 2022 - annualreviews.org
The microtubule (MT) cytoskeleton provides the architecture that governs intracellular
organization and the regulated motion of macromolecules through the crowded cytoplasm …
organization and the regulated motion of macromolecules through the crowded cytoplasm …
Plk1 promotes renal tubulointerstitial fibrosis by targeting autophagy/lysosome axis
Y Du, Y Shang, Y Qian, Y Guo, S Chen, X Lin… - Cell Death & …, 2023 - nature.com
The prevalence of chronic kidney disease (CKD) has been increasing over the past
decades. However, no effective therapies are available for delaying or curing CKD …
decades. However, no effective therapies are available for delaying or curing CKD …
Role of TSC1 in physiology and diseases
Since its initial discovery as the gene altered in Tuberous Sclerosis Complex (TSC), an
autosomal dominant disorder, the interest in TSC1 (Tuberous Sclerosis Complex 1) has …
autosomal dominant disorder, the interest in TSC1 (Tuberous Sclerosis Complex 1) has …